Physician profile
Nader Ismail
NPI 1689135618
$1,536.47
in general payments reported to CMS, 2019-2025
23 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $141 · 2024: $226 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516 · Education: $20.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.54 |
| Education | $20.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $195.71 | 2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $190.79 | 2023-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $163.22 | 2024-2025 | |
| Ardelyx, INC. | $159.47 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $118.86 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $102.58 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $90.12 | 2024-2025 | Acthar |
| Fresenius USA Marketing, INC. | $88.34 | 2024-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $65.71 | 2025 | |
| Genentech USA, INC. | $42.31 | 2025 | Gazyva |
| Ani Pharmaceuticals, INC. | $41.49 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $31.27 | 2023 | Strensiq |
| Akebia Therapeutics INC | $28.97 | 2025 | Vafseo |
| Novo Nordisk INC | $25.53 | 2025 | Ozempic |
| Scpharmaceuticals INC. | $24.97 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $24.95 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $24.79 | 2025 | Gattex |
| Opko Pharmaceuticals, LLC | $20.93 | 2024 | Rayaldee |
| Lilly USA, LLC | $20.79 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.80 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.75 | 2023 | Lokelma |
| Glaxosmithkline, LLC. | $18.59 | 2025 | Shingrix |
| Ultragenyx Pharmaceutical INC. | $17.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.